About this trial
This human laboratory study will collect preliminary safety and efficacy data from a sample of participants enrolled in a 4-week in-patient treatment program for alcohol use disorder.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 21-65 years old
Enrolled at Ashley Addiction Treatment center at least one week prior to beginning study participation.
Meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for Alcohol Use Disorder
Willing to comply with the study protocol
Disqualifiers
Score 9 or greater on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) at randomization
Currently pregnant, breastfeeding
Unwilling to use contraceptives (e.g., condoms and/or hormonal birth control)
Meet criteria for another substance use disorder other than AUD, Tobacco Use Disorder, or Caffeine use disorder
Trial design
Parallel
Treatments tested in this trial
Placebo
DrugOver-encapsulated non-active microcrystalline cellulose
Glucagon-Like Peptide-1 Agonist (GLP-1)
DrugOver-encapsulated Glucagon-Like Peptide-1 Agonist (GLP-1) oral tablets
Naltrexone (oral tablets)
DrugOver-encapsulated Naltrexone (oral tablets)
Treatment groups
Trial outcomes
Primary outcomes
Participant-reported Adverse Events
Participant-reported adverse events during the course of the trial
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: